Satellos Bioscience Inc.
MSLEHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeSatellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and. Valued at $136.2M, MSLE is a micro-cap name in its sector. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Market Cap
$136.2M
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-2.46
EPS (TTM)
$-1.89
EPS (Fwd)
$-2.61
ROE
-70.5%
ROA
-41.9%
Cash
$61.8M
Total Debt
$0
Free CF
-$16.9M
52W Change
0.2%
Annual Financials
Cash vs Debt
Where MSLE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MSLE finished 19.10% below its 150-day moving average ($7.96) and 24.15% below its 200-day moving average ($8.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MSLE overbought or oversold?
At the October 20, 2026 close, MSLE's RSI(14) was 14.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Satellos Bioscience Inc. reports $61.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$16.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -70.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MSLE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.